Aldosterone, mineralocorticoid receptor, and heart failure
- PMID: 21784127
- DOI: 10.1016/j.mce.2011.06.038
Aldosterone, mineralocorticoid receptor, and heart failure
Abstract
Several large clinical studies have demonstrated the important benefit of mineralocorticoid receptor (MR) antagonists in patients with heart failure, left ventricular dysfunction after myocardial infarction, hypertension or diabetic nephropathy. Aldosterone adjusts the hydro-mineral balance in the body, and thus participates decisively to the control of blood pressure. This traditional view of the action of aldosterone restricted to sodium reabsorption in epithelial tissues must be revisited. Clinical and experimental studies indicated that chronic activation of the MR in target tissues induces structural and functional changes in the heart, kidneys and blood vessels. These deleterious effects include cardiac and renal fibrosis, inflammation and vascular remodeling. It is important to underscore that these effects are due to elevated MR activation that is inadequate for the body salt requirements. Aldosterone is generally considered as the main ligand of MR. However, this is a matter of debate especially in heart. Complexity arises from the glucocorticoids with circulating concentrations much higher than those of aldosterone, and the fact that the MR has a high affinity for 11β-hydroxyglucocorticoids. Nevertheless, the beneficial effects of MR inhibition in patients with heart failure emphasize the importance of this receptor in cardiovascular tissue. Diverse experimental models and strains of transgenic mice have allowed to dissect the effects of aldosterone and the MR in the heart. Taken together experimental and clinical data clearly highlight the deleterious cardiovascular effects of MR stimulation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.Eur J Clin Invest. 2012 Oct;42(10):1112-20. doi: 10.1111/j.1365-2362.2012.02676.x. Epub 2012 Apr 26. Eur J Clin Invest. 2012. PMID: 22536780 Review.
-
RALES, EPHESUS and redox.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):121-5. doi: 10.1016/j.jsbmb.2004.12.010. Epub 2005 Jan 28. J Steroid Biochem Mol Biol. 2005. PMID: 15860254 Clinical Trial.
-
The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism.Mol Cell Endocrinol. 2012 Mar 24;350(2):281-8. doi: 10.1016/j.mce.2011.09.011. Epub 2011 Sep 10. Mol Cell Endocrinol. 2012. PMID: 21945603 Review.
-
Mineralocorticoid receptors in the metabolic syndrome.Trends Endocrinol Metab. 2009 Nov;20(9):444-51. doi: 10.1016/j.tem.2009.05.006. Epub 2009 Sep 30. Trends Endocrinol Metab. 2009. PMID: 19800255 Review.
-
Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models.Mol Cell Endocrinol. 2004 Mar 31;217(1-2):127-36. doi: 10.1016/j.mce.2003.10.045. Mol Cell Endocrinol. 2004. PMID: 15134811 Review.
Cited by
-
Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.FASEB J. 2015 Nov;29(11):4544-54. doi: 10.1096/fj.15-276782. Epub 2015 Jul 15. FASEB J. 2015. PMID: 26178166 Free PMC article.
-
Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.Heart Fail Rev. 2016 Nov;21(6):699-701. doi: 10.1007/s10741-016-9583-2. Heart Fail Rev. 2016. PMID: 27620301 Review.
-
The ubiquitous mineralocorticoid receptor: clinical implications.Curr Hypertens Rep. 2012 Dec;14(6):573-80. doi: 10.1007/s11906-012-0297-0. Curr Hypertens Rep. 2012. PMID: 22843494 Free PMC article. Review.
-
Left ventricular geometry and 24-h blood pressure profile in Cushing's syndrome.Endocrine. 2017 Feb;55(2):547-554. doi: 10.1007/s12020-016-0986-6. Epub 2016 May 14. Endocrine. 2017. PMID: 27179657
-
Aldosterone mediates cardiac fibrosis in the setting of hypertension.Curr Hypertens Rep. 2013 Aug;15(4):395-400. doi: 10.1007/s11906-013-0354-3. Curr Hypertens Rep. 2013. PMID: 23686824 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical